Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 9;24(18):13888.
doi: 10.3390/ijms241813888.

Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses

Annalisa Chianese  1 , Carla Zannella  1 , Alessandra Monti  2 , Nunzianna Doti  2 , Giuseppina Sanna  3 , Aldo Manzin  3 , Anna De Filippis  1 , Massimiliano Galdiero  1
Affiliations

Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses

Annalisa Chianese et al. Int J Mol Sci. .

Abstract

Pandemic and epidemic outbreaks of respiratory viruses are a challenge for public health and social care system worldwide, leading to high mortality and morbidity among the human populations. In light of the limited efficacy of current vaccines and antiviral drugs against respiratory viral infections and the emergence and re-emergence of new viruses, novel broad-spectrum antiviral drugs are needed for the prevention and treatment of these infections. Antimicrobial peptides with an antiviral effect, also known as AVPs, have already been reported as potent inhibitors of viral infections by affecting different stages of the virus lifecycle. In the present study, we analyzed the activity of the AVP Hylin-a1, secreted by the frog Hypsiboas albopunctatus, against a wide range of respiratory viruses, including the coronaviruses HCoV-229E and SARS-CoV-2, measles virus, human parainfluenza virus type 3, and influenza virus H1N1. We report a significant inhibitory effect on infectivity in all the enveloped viruses, whereas there was a lack of activity against the naked coxsackievirus B3. Considering the enormous therapeutic potential of Hylin-a1, further experiments are required to elucidate its mechanism of action and to increase its stability by modifying the native sequence.

Keywords: SARS-CoV-2; antimicrobial peptide; coronavirus; emerging infection; influenza; inhibitory peptide; respiratory viruses.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Hylin-a1 cytotoxic activity. Cells were treated with peptide at several concentrations ranging from 0.39 to 100 μM. After 2 and 24 h of treatment, cell viability was obtained by the spectrophotometer analysis of the MTT assay. Cells without peptide were used as a negative control (CTRL −), whereas DMSO was used as a positive control (CTRL +). **** p < 0.0001; ns: non-significant.
Figure 2
Figure 2
Antiviral activity against HCoV. Different assays (co-treatment, cell pre-treatment, post-treatment, and virus pre-treatment) were conducted in order to test the anti-HCoV activity. (A) Co-treatment; (B) cell pre-treatment; (C) post-treatment; (D) virus pre-treatment. Infected cells without peptide were used as controls (CTRL −). **** p < 0.0001; *** p < 0.001; ns: non-significant.
Figure 3
Figure 3
Antiviral activity against paramyxoviruses. Different assays were used to investigate the anti-MeV and anti-HPIV-3 activities. (A) Co-treatment; (B) cell pre-treatment; (C) post-treatment; (D) virus pre-treatment. Infected cells without peptide were used as controls (CTRL −). **** p < 0.0001; ns: non-significant.
Figure 4
Figure 4
Antiviral activity against RSV. (A) Plaque assay. Co-treatment was performed and viral plaques observed after 48 h. Infected cells without peptide were used as controls (CTRL –). (B) RSV F protein ELISA. The binding of cells to the F protein was analyzed both in the absence and presence of Hylin-a1. **** p < 0.0001; *** p < 0.001; ns: non-significant.
Figure 5
Figure 5
Antiviral activity against influenza virus. Different assays were carried out to verify the anti-influenza virus activity. (A) Co-treatment; (B) cell pre-treatment; (C) post-treatment; (D) virus pre-treatment. Infected cells without peptide were used as controls (CTRL –). **** p < 0.0001; ns: non-significant.
See this image and copyright information in PMC

References

    1. Okomo U., Idoko O.T., Kampmann B. The burden of viral respiratory infections in young children in low-resource settings. Lancet Glob. Health. 2020;8:e454–e455. doi: 10.1016/s2214-109x(20)30037-1. - DOI - PubMed
    1. Wang X., Li Y., O’Brien K.L., Madhi S.A., Widdowson M.-A., Byass P., Omer S.B., Abbas Q., Ali A., Amu A., et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study. Lancet Glob. Health. 2020;8:e497–e510. doi: 10.1016/s2214-109x(19)30545-5. - DOI - PMC - PubMed
    1. Blau D.M., Baillie V.L., Els T., Mahtab S., Mutevedzi P., Keita A.M., Kotloff K.L., Mehta A., Sow S.O., Tapia M.D., et al. Deaths Attributed to Respiratory Syncytial Virus in Young Children in High–Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS) Clin. Infect. Dis. 2021;73((Suppl. S3)):S218–S228. doi: 10.1093/cid/ciab509. - DOI - PMC - PubMed
    1. Chuang Y.-C., Lin K.-P., Wang L.-A., Yeh T.-K., Liu P.-Y. The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. Infect. Drug Resist. 2023;16:661–675. doi: 10.2147/idr.s396434. - DOI - PMC - PubMed
    1. Lin C.-Y., Hwang D., Chiu N.-C., Weng L.-C., Liu H.-F., Mu J.-J., Liu C.-P., Chi H. Increased Detection of Viruses in Children with Respiratory Tract Infection Using PCR. Int. J. Environ. Res. Public Health. 2020;17:564. doi: 10.3390/ijerph17020564. - DOI - PMC - PubMed